AI によるプラーク定量化: 効果的な CAD 管理を決定するための CCTA および AI-QCPA (DECIDE)
DECIDE レジストリ: AI 由来のプラーク定量化: 効果的な CAD 管理を決定するための CCTA および AI-QCPA
The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).
調査の概要
詳細な説明
The DECIDE Registry is a post-market, multi-center, data collection study assessing the change in management of clinically stable patients who undergo CCTA with plaque detected. Data will be retrospectively collected following the CCTA, and analyses will be completed 90 days, 180 days, and 1 year after CCTA. Data may be retrospectively collected annually up to 5 years.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
North Carolina
-
Greensboro、North Carolina、アメリカ、27401
- Moses Cone Memorial Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Deidentified data will be collected for all patients who have had a CCTA with plaque detected or a stress test and are included by the site in the registry.
説明
Inclusion Criteria (all must be present) :
- Groups 1, 2,4,5 and 6: CCTA and plaque detected
- Group 3: Any patient with a stress test (stress echocardiogram or nuclear imaging including SPECT or PET) and no CCTA within the 90 days prior to site activation
- Groups 1,2,3 and 4: Clinically stable, symptomatic
- Group 6: Clinically stable without symptoms suggestive of CAD at the time of the CCTA
Exclusion Criteria (all must be absent) :
- ED presentation (at the time of the CCTA or stress test)
- Groups 1,2,3,4, and 6: Previous history of CAD (prior to the CCTA or stress test with history of revascularization)
- Group 5: Prior history of PCI in multiple vessel territories, PCI in the Left Main, CABG, and/or any other conditions or limitations which would prevent successful CCTA processing by HeartFlow
- Acute chest pain (in patients who have not been ruled out for ACS)
- Previously evaluated with and/or in a study which includes AI-QCPA
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:CROSS_SECTIONAL
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Group 1: No AI-QCPA
This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. No AI-QCPA will be provided. |
|
|
Group 2: Delayed AI-QCPA
This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. Ninety days following the CCTA, an AI-QCPA report will be provided to the CCTA reader who will in turn provide it to the treating clinician. The treating clinician will decide if changes to medical management are required to effectively treat the patient and if so, treating clinician will contact the patient with the new treatment plan. |
The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA. |
|
Group 3: Stress Test Only
This group includes symptomatic patients who previously had non-invasive stress testing only with no CCTA and no prior revascularization. No AI-QCPA will be provided. |
|
|
Group 4: Prospective AI-QCPA, symptomatic without prior revascularization
This group includes newly scanned, symptomatic patients with plaque detected and no prior revascularization. Patients in this group will have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient. |
The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA. |
|
Group 5: Prospective AI-QCPA, prior PCI
This group includes newly scanned patients with plaque detected. Patients in this group can by symptomatic or asymptomatic and will have had prior PCI in only one vessel territory (CABG patients are not eligible). CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient. |
The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA. |
|
Group 6: Prospective AI-QCPA, asymptomatic without prior revascularization
This group includes newly scanned, asymptomatic patients with plaque detected and no prior revascularization. Patients in this group will not have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient. |
The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary Endpoint
時間枠:90 Days
|
The primary endpoint of the DECIDE Registry is the change in medical management following HeartFlow AI-QCPA at 90 days compared to medical management following CCTA alone. The primary endpoint will only be assessed in patients in Group 2. |
90 Days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in LDL levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Change in HbA1c levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Changes in Non HDL levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Changes in HDL levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Changes in TG levels
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Changes in weight
時間枠:From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Reclassification rate of medical management (across the groups)
時間枠:90 Days, 180 Days and 365 Days
|
Change in preventive medical management (lower or intensify). |
90 Days, 180 Days and 365 Days
|
|
Rates of referral to invasive coronary angiography and coronary revascularization (PCI+CABG)
時間枠:90 Days, 180 Days and 365 Days
|
across the groups |
90 Days, 180 Days and 365 Days
|
|
Reclassification rate of symptoms
時間枠:90 Days, 180 Days and 365 Days
|
Improvement in symptoms across the groups |
90 Days, 180 Days and 365 Days
|
|
Number of CV hospitalizations
時間枠:At 365 Days (and potentially out to 5 years)
|
across the groups |
At 365 Days (and potentially out to 5 years)
|
|
Number of Revascularizations
時間枠:365 Days
|
At one year across the groups |
365 Days
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of MACE (CV-related death, MI, or CAD hospitalization)
時間枠:At 365 Days (and potentially out to 5 years)
|
Exploratory & safety endpoints will be compared across the groups unless otherwise noted |
At 365 Days (and potentially out to 5 years)
|
|
Timing of referral to other provider(s) for management
時間枠:Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
|
across the groups unless otherwise noted |
Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
|
|
Timing of lab orders (Group 1 vs. Group 2)
時間枠:Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
|
across the groups unless otherwise noted |
Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
|
|
Change in Lp(a) (Group 2)
時間枠:Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups unless otherwise noted |
Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Change in Lp(a) (Group 4 compared to Group 1)
時間枠:Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups unless otherwise noted |
Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Rate of cardiac testing
時間枠:At 365 Days (and potentially out to 5 years)
|
Efficiency of testing based upon imaging and reports for all other cardiac tests including CCTA, SPECT, echo, CAC, and stress echo |
At 365 Days (and potentially out to 5 years)
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Sarah Rinehart, MD、CAMC Health System
- 主任研究者:Leslee Shaw, MD、MOUNT SINAI HOSPITAL
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。